# Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

> **NCT05012787** · PHASE3 · TERMINATED · sponsor: **Clover Biopharmaceuticals AUS Pty** · enrollment: 1 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- **BIOLOGICAL:** Havrix
- **OTHER:** Placebo; 0.9% saline

## Key facts

- **NCT ID:** NCT05012787
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-12
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-05-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was early terminated considering the inability to enroll the required study population.
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012787, "Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05012787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*